Immunotherapeutic efficacy of recombinant canine IL-15 as an adjunct to chemotherapy in canine lymphoma.

rcIL-15 adjuvant to chemotherapy improves lymphoma response and quality of life in dogs.

This randomized controlled trial evaluated recombinant canine interleukin-15 (rcIL-15) as an adjunctive immunotherapy to standard chemotherapy in 61 dogs with lymphoma. The 12-week study compared 37 dogs completing treatment (test group receiving rcIL-15 plus chemotherapy versus control group receiving chemotherapy alone). The test group achieved a superior overall response rate of 77.8% versus 57.9% in controls, with lower disease progression rates (16.7% versus 31.6%). Tumor biomarker analysis demonstrated significant reductions in TK-1, LDH, and β2-microglobulin levels in the rcIL-15 group at study endpoints. Quality of life parameters, including appetite, activity, and happiness scores, showed significant improvement in treated dogs. Adverse events were predominantly mild gastrointestinal effects and were readily manageable. The study demonstrates that adjunctive rcIL-15 therapy enhances therapeutic outcomes in canine lymphoma while maintaining an acceptable safety profile. These findings suggest rcIL-15 represents a promising immunotherapeutic strategy warranting larger-scale confirmatory trials.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.